Axsome Therapeutics
AXSM
35 hedge funds and large institutions have $35.3M invested in Axsome Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 20 closing their positions.
17% more capital invested
Capital invested by funds: $30.2M → $35.3M (+$5.01M)
6.74% less ownership
Funds ownership: 33.86% → 27.12% (-6.7%)
29% less funds holding
Funds holding: 49 → 35 (-14)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$419K |
| 2 |
Millennium Management
New York
|
+$331K |
| 3 |
ECM
Element Capital Management
New York
|
+$257K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$205K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.86M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.56M |
| 3 |
JP Morgan Chase
New York
|
-$670K |
| 4 |
OPPM
Opus Point Partners Management
New York
|
-$559K |
| 5 |
State Street
Boston,
Massachusetts
|
-$540K |
AXSM Hedge Fund Activity: Q2 2017 in Review
35 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2017, worth a combined $35.3M — up 17% from $30.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AXSM and 6 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Sphera Funds Management, adding an estimated $419K. The largest seller was BlackRock, cutting an estimated $1.86M.
- 35 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2017, down from 49 in Q1 2017.
- Funds reported $35.3M of Axsome Therapeutics stock for Q2 2017, up 17% quarter-over-quarter.
- 6 funds opened new Axsome Therapeutics positions in Q2 2017 and 20 closed out, a net change of -14 holders.
- The largest Axsome Therapeutics buyer in Q2 2017 was Sphera Funds Management, an estimated $419K added.
- The largest Axsome Therapeutics seller in Q2 2017 was BlackRock, an estimated $1.86M sold.
Based on aggregated 13F filings for Q2 2017.